Moderna shares jump as cancer-vaccine enthusiasm keeps driving the stock higher

Moderna (MRNA) is up 10.6% today. Here is some analysis on what might have caused this price movement. ([finance.yahoo.com](https://finance.yahoo.com/healthcare/articles/moderna-climbs-6-cancer-vaccine-135031898.html?utm_source=openai))

Analysis: The most likely driver is continued investor enthusiasm around Moderna’s personalized cancer vaccine program, rather than a brand-new company announcement today. This could also be because investors are positioning ahead of expected late-2026 Phase 3 melanoma data after the company highlighted durable Phase 2b results and ongoing oncology expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm?utm_source=openai))

Details:

Moderna’s second-quarter 2026 materials said its intismeran program, developed with Merck, has nine Phase 2 and Phase 3 trials running across melanoma, lung, bladder, and kidney cancers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm?utm_source=openai))

Those same materials said Phase 3 adjuvant melanoma data could arrive in 2026, keeping attention on a potentially important late-year readout. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm?utm_source=openai))

A May 2026 oncology update showed five-year Phase 2b melanoma data with a 49% reduction in recurrence or death risk for intismeran plus pembrolizumab versus pembrolizumab alone. ([ascopubs.org](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.9500?utm_source=openai))

Market coverage on September 17 noted the rally appeared to be an extension of that cancer-vaccine trade and said there was no fresh disclosure attached to the move. ([finance.yahoo.com](https://finance.yahoo.com/healthcare/articles/moderna-climbs-6-cancer-vaccine-135031898.html?utm_source=openai))

Sources:

Moderna Investor Relations, SEC, Yahoo Finance ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm?utm_source=openai))

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
STEPHEN HOGE (President) has made 0 purchases and 5 sales selling 240,583 shares for an estimated $20,618,266.
JAMES M MOCK (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,836 shares for an estimated $4,685,093.
SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,942 shares for an estimated $659,316.
NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MRNA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MRNA Hedge Fund Activity

We have seen 382 institutional investors add shares of $MRNA stock to their portfolio, and 396 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 6,187,867 shares (+13.5%) to their portfolio in Q2 2026, for an estimated $433,336,326
D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,838,884 shares (+inf%) to their portfolio in Q2 2026, for an estimated $338,867,046
CAPITAL WORLD INVESTORS added 3,579,302 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $250,658,519
ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330
BAILLIE GIFFORD & CO removed 2,373,736 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $166,232,732

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRNA Congressional Stock Trading

Members of Congress have traded $MRNA stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by members of Congress over the last 6 months:

REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/19 and 1 sale worth up to $15,000 on 08/19.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 8 analysts offer price targets for $MRNA in the last 6 months, with a median target of $46.5.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
Eliana Merle from UBS set a target price of $45.0 on 05/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.